Reply to Article by Margolese and Associates on Tolerance and Rebound During Maintenance With Quetiapine
Abstract
Journal of Clinical Psychopharmacology 24(1):p 102-103, February 2004. | DOI: 10.1097/01.jcp.0000106231.36344.f8
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Persistent post-withdrawal disorders, defined as rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type persisting longer than 6 weeks, have been described after discontinuation of antipsychotics.
“Persistent post-withdrawal disorders, that is a condition in which rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type, such as disorganized behavior, persist longer than 6 weeks, have been described after discontinuation of antipsychotics.”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [151]
Two specific persistent post-withdrawal disorders, persistent post-withdrawal tardive dyskinesia and persistent post-withdrawal supersensitivity psychosis, have been well described.
“2 specific persistent post-withdrawal disorders, named persistent post-withdrawal tardive dyskinesia and persistent post-withdrawal supersensitivity psychosis, have been well described [21, 22, 150, 151].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [151]
Chouinard et al. concluded that 2 persistent post-withdrawal disorders, tardive dyskinesia and supersensitivity psychosis, were specifically induced by antipsychotics.
“and that 2 persistent post-withdrawal disorders, tardive dyskinesia and supersensitivity psychosis, were specifically induced by antipsychotics [21, 22, 150, 151].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [151]
Cites
Relapse and Rehospitalisation Rates in Patients with Schizophrenia
Csernansky, J. G., & Schuchart, E. K. (2002) · CNS Drugs · doi:10.2165/00023210-200216070-00004 · Cited by 181 · see citing works
Margolese, H. C., Chouinard, G., Beauclair, L., & Bélanger, M.-C. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00003 · Cited by 61 · see citing works
Pharmacological prevention of relapse.
LADER, M. H. (1998) · PubMed · Cited by 10 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270 · see citing works
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · see citing works
- Authors
- Goldstein, J., & Macfadden, W.
- Affiliations
- AstraZeneca (United States) (US)
- ORCID
- Macfadden, Wayne
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2004-02
- Volume
- 24
- Issue
- 1
- Pages
- 102-103
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2093463508
- Cited by
- 2
- References
- 3
- Citations by year
- 2020: 1 · 2017: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- quetiapine, antipsychotic maintenance, drug tolerance, rebound effect, antipsychotic treatment response
- MeSH terms
- Quetiapine Fumarate, Dibenzothiazepines, Drug Administration Schedule, Drug Tolerance, Humans, Psychotic Disorders, Recurrence, Retrospective Studies, Antipsychotic Agents, Meta-Analysis as Topic, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
